Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer.

Ruo-Kai LinChih-Ming SuShih-Yun LinLe Thi Anh ThuPhui-Ly LiewJian-Yu ChenHuey-En TzengYun-Ru LiuTzu-Hao ChangCheng-Yang LeeChin-Sheng Hung

Published in: Molecular medicine (Cambridge, Mass.) (2022)

Hypermethylation of TMEM240 is a potential biomarker for treatment response and disease progression monitoring in breast cancer.

Keyphrases